Skip to main content

Table 6 Incidence of drug related adverse events in safety analysis population

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

Drug related adverse events Number (%) of subjects with ADRs  
FMS/RSV MFS RSV p-value
Total number (%) 4 (8.33) 3 (6.52) 5 (11.11) 0.755
Abdominal pain upper - 1 (2.17) -  
Dyspepsia 1 (2.08) - -  
Nausea 1 (2.08) - -  
Headache - - 2 (4.44)  
Pyrexia 1 (2.08) - -  
Hepatitis 1 (2.08) - -  
Hepatic enzyme increased - 1 (2.17) -  
Hyperkalaemia - - 1 (2.22)  
Insomnia - - 1 (2.22)  
Pollakiuria - 1 (2.17) -  
Pruritus - - 1 (2.22)  
  1. ADRs adverse drug reactions, FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment